Phase
Condition
Immune Thrombocytopenia (Itp)
Dysfunctional Uterine Bleeding
Thrombosis
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
ITP with platelet count <30 x 109 /l after 2 weeks of treatment with prednisolon orduring prednisolon tapering period i.e. from week three of prednisolon initiation.Patients with platelet count between 30 -50 are eligible if a higher platelet count isconsidered necessary, because of : concomitant medical illness predisposing tobleeding (hypertension, GI bleeding, bleeding diathesis, previous history of bleeding)concomitant medical condition requiring platelet blocking agents/ anticoagulation,persistent bleeding despite platelets > 30 x 109 /l, prior to surgery, or because ofother patient related factors necessitating higher platelet count as occupation,hobby, psychological intolerability.
Subject is >18 years
Subject has signed and dated written informed consent.
Subject is able to understand and comply with protocol requirements and instructions,and intends to complete the study as planned.
Females in fertile age should express willingness for use of contraceptive means for 6months following the administration of the study drugs.
Exclusion
Exclusion criteria:
Previous splenectomy, chemotherapy, treatment with anti-D Ig, rituximab, orimmune-suppressive treatments other than corticosteroids, Dapsone or Danazol
Underlying malignancy or previous history of malignancy in the past 5 years (exceptskin carcinoma)
Pregnancy and lactation
Not willing to participate in the study
Expected survival of < 2 years
Known intolerance to murine antibodies
Females in child-bearing age not willing to use contraception for 6 months
HIV-positive/AIDS-, Hepatitis -B virus positive- or Hepatitis -C virus positive
Patients with a definite Systemic Lupus Erythematosus (SLE) (> 4 of the AmericanCollege of Rheumatology Criteria)
Patients currently involved in another clinical trial with evaluation of drugtreatment
Bacterial infections, viral infections, fungal infections, myco-bacterial infections (excluding fungal infections) or other evolutive infections or any other infectionsepisode requiring hospitalisation or treatment with an antibiotics 4 weeks beforeselection for IV route or within 2 weeks before selection for oral route
History of soft tissue, bone or joint infections (fascitis, abscess, osteomyelitis,septic arthritis) during the last year prior to inclusion in the study
Medical history of relapsing or chronic severe infectious diseases or any otherunderlying pathology predisposing to serious infections
Known Primary or secondary immune deficiency syndromes
Administration of a living vaccine within 4 weeks preceding the inclusion in the study -16- Previous treatment with any lymphocytes depleting medication (e.g.: MabCampath®)
17- Previous treatment with inhibitors of leucocytes transmigration (e.g.: Tysabri®) 18-Known intolerance to human monoclonal antibodies 19- Known severe chronic pulmonaryobstructive Disease (FEV < 50% or functional dyspnoea grade 3) 20- Known congestive heartfailure NYHA (New York Heart Association classification of heart failure) class III and IV 21- Recent episode (<6 months) of acute coronary syndrome.
Study Design
Study Description
Connect with a study center
Østfold Hospital Trust in Fredrikstad and National hospital in Oslo
Fredrikstad and Oslo, 1603
NorwaySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.